Translate
Ronny Allan
Award winning Neuroendocrine Cancer Patient Advocate. Diagnosed with Metastatic Neuroendocrine Cancer in 2010.
I always try to use graphics for a number of pictures, I admit mainly to catch people’s attention but also because sometimes a picture on its own tells a story or at least provides a great introduction to one.
If the picture catches your eye, clicking on will take you to the text. This post will auto update as new blogs are published.
thanks for reading and sharing!
Pancreatic NET with carcinoid syndrome – not as common as you think
A spotlight on Appendiceal Neuroendocrine Neoplasms
Nuclidium wins award to study NET radiopharmaceutical – Phase 1 Clinical Trial of TraceNET (TM)
Experimental drug for Gastric NET – Netazepide
A Newsletter from RonnyAllan.NET – 13th March 2023
Fructose intolerance – the NET Effect
A tribute to the life and legacy of Miranda Filmer
Treatment for Neuroendocrine Cancer: Beware of the alternatives
RonnyAllan.NET – Summary of February 2023 – Ronny Allan – Living with Neuroendocrine Cancer
A spotlight on Gastric Neuroendocrine Neoplasms
Sometimes I climb hills just to piss my cancer off
Belzutifan for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), or Von Hippel-Lindau (VHL) Disease-Associated Tumors
A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
A Newsletter from RonnyAllan.NET – 12th February 2023
RonnyAllan.NET – Summary of January 2023 – Ronny Allan – Living with Neuroendocrine Cancer
Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies (incl NET)
Dustin Diamond
Neuroendocrine tumors are uncommon but definitely not rare
Cancer Ablation
Lactose intolerance – the NET Effect
EUS Guided Ablation for small pancreatic NETs (Less than 2cm)
RonnyAllan.NET – a review of 2022
RonnyAllan.NET – Summary of December 2022
Happy New Year from Ronny
Piss off cancer – 12 years of Christmas and I’m still here!
A Christmas 2022 message from Ronny
A multicentre validation of the NETPET score (Dual [68Ga]DOTATATE and [18F]FDG PET/CT in patients with metastatic GEPNENs
Stereotactic body radiation therapy (SBRT) in the treatment of Neuroendocrine Neoplasms
Lanreotide: 12 more years
RonnyAllan.NET – Summary of November 2022
In the news – new Neuroendocrine Tumour PET Fluorine-18 based ‘tracer’
Incurable isn’t terminal
The Inspirational Wilko Johnson: 12 July 1947 – 21 November 2022
Neuroendocrine Neoplasms (NEN) – genetic related syndromes
Neuroendocrine Cancer: Those who know, know!
Ask More, Assume Less
Piss off Cancer, it’s been 12 years since my “big surgery”
Neuroendocrine Cancer: 10 questions your dietitian will ask
Neuroendocrine Cancer: Beware But Be Aware
Incidental Findings in Somatostatin Receptor PET (SSTR PET) scans (e.g. Ga68/Cu64)
RonnyAllan.NET – Summary of October 2022
Alpha-emitter PRRT: Phase 1/2 Study of AlphaMedix™ (²¹²Pb-DOTAMTATE) in Adult Subjects With SSTR positive NET
How are you, Doctor?
Benign liver lesions and cysts – something or nothing?
Understanding your Somatostatin Receptor (SSTR) PET Results
Evolving Approaches in the Management of Neuroendocrine Tumor-Associated Carcinoid Syndrome
The Hidden Pheochromocytoma
New test of pancreatic cysts to help with cancer detection
Evidence of disease but stable
Study of Lu-177-DOTATATE (Lutathera) in Combination With PARP Inhibitors in Inoperable/Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)
Neuroendocrine Cancer: Glossary of Terms
Opinion: On Rare Cancer Day, what’s wrong with a bit of Neuroendocrine Cancer awareness?
Prospective Phase II Trial of Prognostication by 68Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted Therapy
Living with cancer: 5 tips for facing things you can’t control
A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors (MAST)
Neuroendocrine Cancer: When you get years added to your life, it’s important to get life added to your years
Opinion: Neuroendocrine Cancer – remission, cancer-free, no evidence of disease
Clinical Trial: Phase 1b/3 Targeted Alpha-Emitter PRRT RYZ101 (Ac225)
Lung nodules – something or nothing?
Awareness Post – Neuroendocrine Cancer in children and adolescents
Eat that doughnut!
Thyroid nodules – something or nothing?
Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial
Prospective phase II trial of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET/CT imaging of integrin for prognostication in patients with neuroendocrine neoplasms
Neuroendocrine Cancer: At least 50 shades of grey
Curtis Crump: “If I’m going down, it won’t be without a fight.”
The trouble with the NET is that it can spread ……. false hope
Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients receiving Concomitant 225Ac-DOTATATE Targeted Alpha Therapy and Capecitabine: A Real-world Scenario Management Based Long-term Outcome Study
12 years – I’m still here!
Neuroendocrine Cancer: turn surveillance into a positive
Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial
Neuroendocrine Cancer: diagnostic dilemmas in July 2010
CT scan findings in the COVID era: Ground Glass Opacities (GGO)
Me and the other big C – June/July 2022
New PET findings after COVID-19 vaccination: Keep Calm and Carry On?
Clinical Trial: Triapine and Lutetium Lu 177 Dotatate for Neuroendocrine Tumors
CAPTEM for Neuroendocrine Tumours
Living with Cancer: Don’t cross the bridge until you come to it
Clinical Trial: Dostarlimab, anti–PD-1 monoclonal antibody in Neuroendocrine Carcinoma
Low and High Residue Foods
On the Cancer Journey, don’t forget to live your life
Histotripsy: A new technique which destroys cancer using soundwaves (now in Clinical Trials)
We are still here!
My illness may be invisible, but I am not – Neuroendocrine Cancer
Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide)
Clinical Trial: Mycapssa (octreotide capsules) for Neuroendocrine Tumours
Clinical Trial: Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
A Spotlight on Lung Neuroendocrine Neoplasms
The trouble with the NET (Part 5) – Cancer Diet Myths
External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy
Clinical Trial: Lutathera and ASTX727 in Neuroendocrine Tumours (LANTana)
Blog review and top 10 for 2021: RonnyAllan.NET
Neuroendocrine Cancer Diarrhea- building the jigsaw: Bile Acid Malabsorption
177Lu-DOTA-LM3 – a novel radionuclide therapy proven safe and effective to treat neuroendocrine neoplasms (NEN)
Small Intestine Neuroendocrine Tumours: “No other cancer really looks like this”
20th November 2010 – feeling perkier
Do we need a new model for Carcinoid Crisis in NETs?
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With GEP-NET (SORENTO)
CAR-T clinical trials for Neuroendocrine Cancer
Opinion: On World Neuroendocrine Cancer Day, what’s wrong with a bit of Neuroendocrine Cancer awareness?
In the land of small tumours, there is still a lot of work to do!
The psychological impact of COVID-19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerability
Q. The best diet for Neuroendocrine Cancer? A. The one that works for you.
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) – (COMPOSE)
New Clinical Trial – Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
The GRAIL multi-cancer early detection test study
Neuroendocrine Tumors: Targeted Therapies – Update from NET Specialist Diane Reidy-Lagunes, MD, Memorial Sloan-Kettering Cancer Center – August 2021
UK Travel Insurance – please give cancer patients a break!
I thought I was going to die. I didn’t
Small Intestine Neuroendocrine Tumours (SI NETs): To cut or not to cut?
Cancer-related fatigue (CRF) – Neuroendocrine Cancer
Let’s Talk About NETs (#LetsTalkAboutNETs)
11 years – I’m still here!
Neuroendocrine Cancer: 48 hours before diagnosis
Every picture tells a story (point, click, read)
A person with Neuroendocrine Cancer fell into a hole and couldn’t get out……….
A painting from America
The 6 E’s
I have walked 500 miles and I will walk 500 more (….. sing along)
Clinical Trial: Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
Neuroendocrine Tumour (VMT-𝛼-NET) programs
Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumours
Generic Somatostatin Analogues for Neuroendocrine Cancer
A Diagnostic Imaging Study of 64Cu-SARTATE™ for Neuroendocrine Tumours
A Neuroendocrine Cancer diagnosis: I didn’t even feel ill
Treatment for Neuroendocrine Cancer – a summary for patients
Ronny Allan Newsletter – 1st March 2021
Opinion: On Rare Disease Day, what’s wrong with a bit of Neuroendocrine Cancer awareness?
My treatment is a pain in the butt!
Ronny Allan – Top 10 for 2020 – Neuroendocrine Cancer
Neuroendocrine Cancer: Follow up tests and checks
Neuroendocrine Cancer – I didn’t hear it coming
Opinion: On World Cancer Day, what’s wrong with a bit of Neuroendocrine Cancer awareness?
Ronny Allan Newsletter – 1st February 2021
Lanreotide and Keytruda – the PLANET study (NCT03043664)
Currently trending on RonnyAllan.NET
The Invisibility of Appendiceal and Colorectal NETs – do the math
Ronny Allan Newsletter – 1st January 2021
A 2020 blog review (RonnyAllan.NET)
Genome methylation accurately predicts neuroendocrine tumor origin – finding Neuroendocrine Neoplasms of unknown primary
Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors – PRRT vs Everolimus
The other Big C can be dangerous too
Neuroendocrine Tumours – now you see them, now you don’t!
Selecting patients and the Challenges of Evaluating Response to PRRT in GEPNETs: The Present and the Future
Lanreotide: Eleven more years please!
2 Million!
Ronny Allan Newsletter 1st December 2020
If it’s not raining, it’s not training! (part 2)
Ronny Allan Newsletter 1st November 2020
Piss off cancer – I’m 67
Early diagnosis of late stage cancer!
Serotonin – it’s a no-brainer!
Paul Hunter Tribute – Snooker champion and Neuroendocrine Cancer patient
Ronny Allan Newsletter 1st October 2020
Clinical Trial: Phase II CLARINET FORTE Somatuline Autogel (Lanreotide) increased dosing frequency
I don’t look sick enough, sorry not sorry
Clinical Trial of Tidutamab in Neuroendocrine Cancer (DUET-1)
“I’m vertical” – Steve Jobs announces to Apple staff after a liver transplant
Flower power and the happy hormones
1.4 million thanks!
RonnyAllan.NET – Newsletter 1st September 2020
Small intestine, large surgery
RonnyAllan.NET – Newsletter 1st August 2020
Paraneoplastic endocrine syndromes – the NET effect
10 years, I’m still here
Don’t be cavalier with a cancer diagnosis
Neuroendocrine Cancer – no sweat!
After lockdown – the new normal is not normal
Living with Neuroendocrine Cancer during COVID-19 restrictions (Episode 12) – a story of surviving, cycling, Scottish holiday memories including the ‘Fairy Pools’
The NETest® – a Chromogranin A replacement and more?
RonnyAllan.NET – Newsletter 1st July 2020
SSTR PET – Ga68-DOTA-JR11 vs Ga68-DOTATATE
Living with Neuroendocrine Cancer during COVID-19 restrictions (Episode 11) – a story of Walking the Wall, coping strategies and the London Ga68 PET
Targeted Therapy for Neuroendocrine Cancer – Sunitinib (Sutent)
Targeted Therapy for Neuroendocrine Cancer – Everolimus (Afinitor)
Ronny Allan: Living with Neuroendocrine Cancer during lockdown (Episode 10) – A story of the Wall, Swans, Dundee and New Forest History
My interview with ITM – I’m still here!
Ronny Allan: Living with Neuroendocrine Cancer during COVID-19 restrictions (Episode 9) – a story of cream teas, peaks and blue sky
RonnyAllan.NET – Newsletter 1st June 2020
Ronny Allan: Living with Neuroendocrine Cancer during COVID-19 restrictions (Episode 8) – a story of nurses, trees and Canada
Ronny Allan: Living with Neuroendocrine Cancer during lockdown restrictions (Episode 7) – A story of swans, cycling, VE Day and my 124th monthly cancer treatment
Ronny Allan: Living with Neuroendocrine Cancer during lockdown restrictions (Episode 6) – A story of footpath etiquette, sheep, donkeys and dopamine
Ronny Allan: Living with Neuroendocrine Cancer during lockdown (Episode 5) – A story of greenery, sun, adventure and Irrfan
Ronny Allan: Living with Neuroendocrine Cancer during COVID-19 restrictions (Episode 4) – A story of bikes, ponies, wisteria and Vitamin D
Ronny Allan: Living with Neuroendocrine Cancer during COVID-19 restrictions (Episode 3) – An injection, hair cut and a broken tooth
Ronny Allan: Living with Neuroendocrine Cancer during COVID-19 restrictions (Episode 2) – the bench walk
Ronny Allan: Living with Neuroendocrine Cancer during COVID-19 restrictions (Episode 1) – out of isolation
Neuroendocrine Cancer Surgery 3: my distant lymph nodes
We Remember – A message of hope in the time of the Coronavirus!
My Self Isolation Diary – COVID-19 2020
COVID-19 and Cancer Treatment and Surveillance
Why Coronavirus Anxiety is Hard to Control – a Neuroendocrine Cancer patient perspective
Coronavirus 19 (COVID-19): risks for cancer patients
Neuroendocrine Cancer Nutrition Series Part 6 – featuring the 2020 video series by Tara Whyand RD
Clinical Trial: Lu-177 DOTATOC (PRRT) in adult subjects with Somatostatin receptor (SSTR) positive Pulmonary, Pheochromocytoma, Paraganglioma, Unknown primary, and Thymic Neuroendocrine Tumors
Oral Octreotide using RaniPill™
Neuroendocrine Cancer: The Perfect Storm
Neuroendocrine Cancer – Liver directed therapy
Featuring Kirsty Dalglish – Pheochromocytoma and Pregnancy
Ronny Allan – Top 10 for 2019 – Neuroendocrine Cancer
NETDetect: Earlier diagnosis of Neuroendocrine Cancer gets a boost
Prognostics and Crystal Balls
Olivia Williams – Neuroendocrine Cancer (VIPoma)
“Please find something wrong with me”
Neuroendocrine Cancer: Double, Double Toil and Trouble
The Flu shot – it’s not just about you
Clinical Trials – PEN-221 for Neuroendocrine Cancer
Clinical Trials – ONC201 for Neuroendocrine Cancer (including Pheo/Para)
The Other 5 E’s
The Case of Justice Ruth Bader Ginsburg vs Cancer
Surufatinib for Neuroendocrine Cancer
The trouble with the NET (Part 4) – Cancer can kill but so can fake cures
Pancreatic Neuroendocrine Tumours – to cut or not to cut
Clinical Trials of PV-10 (Rose Bengal) for the treatment of Neuroendocrine Tumours (NET)
New Radiotracer Can Identify Nearly 30 Types of Cancer – SNMMI – 68Ga-FAPI PET/CT
LUTATHERA (PRRT) – NETTER 2 Clinical Trial for Grade 2/Grade 3 Patients Advanced GEP-NET (NETTER-2)
Clinical Trial of Paltusotine for the Treatment of Neuroendocrine Tumours
The Heterogeneity of Grade 3 (High grade) Neuroendocrine Neoplasms
Clinical Trial: Treatment of IBS with diarrhoea – titrated ondansetron (TRITON)
I’m not sick, I just have cancer
Rosacea – the NET Effect
Neuroendocrine Cancer: No one gets it until they get it!
From dying to living, to hell and back
“I Knew There Was Something Wrong, But I Didn’t Know What” — A Nurse Shares Her Cancer Story
Letter from America
Proton Pump Inhibitors (…..and H2 Blockers) the NET Effect
Clinical Trial: Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors (TALENT)
Clinical Trial: Intra-arterial Lu177 (PRRT) for Neuroendocrine Cancer liver metastases (LUTIA)
Clinical Trial SPARTALIZUMAB – Immunotherapy for Neuroendocrine Neoplasms (PDR001)
Breath test with the goal of detecting multiple cancers – ready to start trials
Q-Sphera™ – Next Generation Somatostatin Analogue delivery system?
Neuroendocrine Cancer: a needle in a haystack?
Neuroendocrine Cancer Clinical Trial – Lutetium-177 OPS-201 (Satoreotide)
